Sarah Kemme1, Marisa Stahl1, Dania Brigham1, Mark A Lovell2, Taizo Nakano3, Amy G Feldman1, Cara Mack1. 1. Section of Gastroenterology, Hepatology and Nutrition, and the Digestive Health Institute, Children's Hospital Colorado, University of Colorado Denver School of Medicine. 2. Section of Pathology and Lab Services, Children's Hospital Colorado, University of Colorado Denver School of Medicine. 3. Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado Denver School of Medicine, Aurora, Colorado.
Abstract
OBJECTIVES: Hepatitis-associated aplastic anemia (HAAA) is a potentially life-threatening diagnosis without clear treatment guidelines. The goal of the study was to characterize the presentation, evaluation, histopathology, and outcomes of therapy in children with HAAA to guide future research and to develop standardized care guidelines for this rare disease. METHODS: Retrospective chart review of 4 patients with HAAA who presented to Children's Hospital Colorado between 2016 and 2019 was conducted. Patient presentation, evaluation, bone marrow and liver pathology, interventions, and clinical course were collected. Immunohistochemistry of liver biopsies was performed. RESULTS: We treated 4 patients with HAAA without liver failure. All had evidence of systemic hyperinflammation and CD8+ T cell predominant liver tissue infiltration. One had a genetic mutation predisposing him to immune-mediated disease, but all other genetic testing was negative. In 3 of the 4 patients, hepatitis was poorly responsive to standard therapy with steroids, azathioprine, or tacrolimus; however, sustained biochemical remission of hepatitis was induced after more aggressive immunosuppressive therapies including Anti-Thymocyte Globulin (ATG) at standard immunosuppressive therapy (IST) dosing for severe Aplastic Anemia (sAA). Two patients underwent hematopoietic stem cell transplant (HSCT); 1 as first line therapy and 1 for refractory sAA. CONCLUSIONS: We found that ATG-based IST induced remission of hepatitis in patients with steroid-refractory HAAA. This is also an appropriate initial treatment for severe Aplastic Anemia, though may not prevent the need for HSCT. We propose that equine ATG based IST at standard dosing regimen for sAA is a therapy that in select cases can be considered early on in the treatment course and could lead to a sustained remission of both hepatitis and sAA. This should be considered in collaboration with a pediatric hematologist.
OBJECTIVES: Hepatitis-associated aplastic anemia (HAAA) is a potentially life-threatening diagnosis without clear treatment guidelines. The goal of the study was to characterize the presentation, evaluation, histopathology, and outcomes of therapy in children with HAAA to guide future research and to develop standardized care guidelines for this rare disease. METHODS: Retrospective chart review of 4 patients with HAAA who presented to Children's Hospital Colorado between 2016 and 2019 was conducted. Patient presentation, evaluation, bone marrow and liver pathology, interventions, and clinical course were collected. Immunohistochemistry of liver biopsies was performed. RESULTS: We treated 4 patients with HAAA without liver failure. All had evidence of systemic hyperinflammation and CD8+ T cell predominant liver tissue infiltration. One had a genetic mutation predisposing him to immune-mediated disease, but all other genetic testing was negative. In 3 of the 4 patients, hepatitis was poorly responsive to standard therapy with steroids, azathioprine, or tacrolimus; however, sustained biochemical remission of hepatitis was induced after more aggressive immunosuppressive therapies including Anti-Thymocyte Globulin (ATG) at standard immunosuppressive therapy (IST) dosing for severe Aplastic Anemia (sAA). Two patients underwent hematopoietic stem cell transplant (HSCT); 1 as first line therapy and 1 for refractory sAA. CONCLUSIONS: We found that ATG-based IST induced remission of hepatitis in patients with steroid-refractory HAAA. This is also an appropriate initial treatment for severe Aplastic Anemia, though may not prevent the need for HSCT. We propose that equine ATG based IST at standard dosing regimen for sAA is a therapy that in select cases can be considered early on in the treatment course and could lead to a sustained remission of both hepatitis and sAA. This should be considered in collaboration with a pediatric hematologist.
Authors: J Tung; N Hadzic; M Layton; A J Baker; A Dhawan; M Rela; N D Heaton; G Mieli-Vergani Journal: J Pediatr Gastroenterol Nutr Date: 2000-11 Impact factor: 2.839
Authors: A B Barroeta Seijas; S Graziani; C Cancrini; A Finocchi; S Ferrari; R Miniero; F Conti; R Zuntini; L Chini; P Chiarello; M Bengala; P Rossi; V Moschese; G Di Matteo Journal: Int J Immunopathol Pharmacol Date: 2012 Apr-Jun Impact factor: 3.219
Authors: R Safadi; R Or; Y Ilan; E Naparstek; A Nagler; A Klein; M Ketzinel-Gilaad; K Ergunay; D Danon; D Shouval; E Galun Journal: Bone Marrow Transplant Date: 2001-01 Impact factor: 5.483
Authors: Zora R Rogers; Taizo A Nakano; Timothy S Olson; Alison A Bertuch; Winfred Wang; Alfred Gillio; Thomas D Coates; Anjulika Chawla; Paul Castillo; Peter Kurre; Christopher Gamper; Carolyn M Bennett; Sarita Joshi; Amy E Geddis; Jessica Boklan; Grzegorz Nalepa; Jennifer A Rothman; James N Huang; Gary M Kupfer; Michaela Cada; Bertil Glader; Kelly J Walkovich; Alexis A Thompson; Rabi Hanna; Adrianna Vlachos; Maggie Malsch; Edie A Weller; David A Williams; Akiko Shimamura Journal: Haematologica Date: 2019-04-04 Impact factor: 9.941